TAS 102

Known as: TAS-102, TAS102, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102 
An orally bioavailable combination agent composed of the cytotoxic pyrimidine analog trifluridine (5-trifluoro-2'-deoxythymidine or TFT) and a… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
The FDA approved TAS-102 (Lonsurf; Taiho Oncology, Inc.) for the treatment of patients with metastatic colorectal cancer (mCRC… (More)
  • table 1
Is this relevant?
2016
2016
BACKGROUND Regorafenib and TAS-102 are novel antitumor agents for patients with metastatic colorectal cancer (mCRC) whose disease… (More)
Is this relevant?
2015
2015
To evaluate safety of TAS-102 administered twice daily (bid) on days 1–5 and 8–12 of a 4-week cycle, confirm feasibility of the… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2014
2014
TAS-102 is a novel oral nucleoside antitumor agent containing trifluridine (FTD) and tipiracil hydrochloride (TPI). The compound… (More)
  • table I
  • table II
  • figure 2
  • figure 1
  • table III
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Treatments that confer survival benefit are needed in patients with heavily pretreated metastatic colorectal cancer… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Background:TAS-102 consists of α, α, α-trifluorothymidine (TFT) and an inhibitor of thymidine phosphorylase (TPI). We conducted a… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2008
2008
TAS-102 is a novel formulation of the fluorinated pyrimidine analogue trifluorothymidine (FTD) with an inhibitor of thymidine… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
2006
2006
BACKGROUND The purpose of the current study was to determine the maximum tolerated dose, dose-limiting toxicities… (More)
Is this relevant?
2004
2004
TAS-102 is a combination drug consisting of alpha,alpha,alpha-trifluorothymidine (FTD) and thymidine phosphorylase inhibitor (TPI… (More)
Is this relevant?
2004
2004
TAS-102 is a new oral anti-cancer drug preparation, composed of a 1:0.5 mixture (on a molar basis) of alpha,alpha,alpha… (More)
Is this relevant?